Dermatology

A phase 2 clinical trial has demonstrated that a once-daily oral tyrosine kinase 2 (TYK2) inhibitor significantly improves symptoms in adults with moderate to severe plaque psoriasis, achieving high clearance rates with a safety profile comparable to placebo.

A new analysis of five clinical trials confirms that dupilumab significantly improves lichenification in patients with moderate to severe atopic dermatitis (AD) across all ages and racial backgrounds.

Artificial intelligence (AI) is becoming a key tool in skin cancer diagnosis, but patient acceptance remains a critical aspect of its implementation.

A recent study has revealed that adult survivors of childhood cancer face a significantly elevated risk of developing melanoma, underscoring the necessity for vigilant long-term monitoring and tailored preventive strategies.

A recent global retrospective cohort study has demonstrated that dupilumab, a monoclonal antibody used to treat atopic dermatitis (AD), offers a favorable cardiometabolic safety profile compared to traditional systemic agents such as methotrexate and cyclosporine.

The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Zabalafin Hydrogel, a novel therapy designed to treat mild to moderate atopic dermatitis (AD) comprehensively.

Long-term data reveal that bimekizumab, a dual IL-17A and IL-17F inhibitor, provides sustained symptom control for patients with hidradenitis suppurativa (HS).

A recent meta-analysis suggests that statin use is associated with improved survival outcomes in patients with cancer undergoing immune checkpoint inhibitor (ICI) therapy.